Nerdwallet Inc vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Nerdwallet Inc trades at $9.81 (market cap $580.74M), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Nuvation Bio Inc. Class A Common Stock is far larger — about 2.9× Nerdwallet Inc's market cap, and Nerdwallet Inc is more actively traded (547,586 versus 5,448,712). Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| NRDS | NUVB | |
|---|---|---|
Market Cap | $580.74M | $1.71B |
Volume | 547,586 | 5,448,712 |
Sector | Media | Health |
52-Week High | $15.93 | $9.54 |
52-Week Low | $7.58 | $3.41 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $495.04M | $1.30B |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.085, up 2.54% with bullish technical signals from moving averages and oscillators. The company shows strong fundamentals with revenue growth from $539M in 2022 to $837M in 2025, improving net income from losses to $49M, and attractive valuation ratios including P/E of 10.09 and P/S of 0.76. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934, but Q1 and Q4 2025 beat estimates.
Outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and a projected 27.9% upside potential. Key risks include competitive pressures in credit cards and small-business products, reliance on organic search traffic, and macroeconomic sensitivity. The stock presents value with strong profitability margins and cash flow generation despite recent earnings volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →